Clomipramine/sildenafil (developmental code name CDFR-0812) is a combination of the tricyclic antidepressant (TCA) and serotonin–norepinephrine reuptake inhibitor (SNRI) clomipramine and the phosphodiesterase PDE5 inhibitor and erectile dysfunction drug sildenafil which is under development for the on-demand treatment of premature ejaculation. It is taken orally. The drug is under development by CTCBIO. As of October 2025, it is in phase 3 clinical trials in South Korea.
See also List of investigational sexual dysfunction drugs
References